The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II study of sunitinib + CXCR4 inhibitor LY2510924 versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.
 
John D. Hainsworth
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Johnson & Johnson (Inst); Lilly (Inst); Novartis (Inst)
 
Joseph Ronald Mace
Consulting or Advisory Role - Spectrum Pharmaceuticals
Speakers' Bureau - Bayer; Pfizer; Spectrum Pharmaceuticals
Travel, Accommodations, Expenses - Bayer; Pfizer; Spectrum Pharmaceuticals
 
James Andrew Reeves
Speakers' Bureau - Celgene
 
Edward J. Crane
No Relationships to Disclose
 
Oday Hamid
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
John R Stille
Employment - Lilly
Stock and Other Ownership Interests - Lilly
Research Funding - Lilly
 
Amy Flynt
Employment - PharPoint Research
 
John Polzer
Employment - Lilly; Lilly (I)
Stock and Other Ownership Interests - Lilly; Lilly (I)
 
Alvin Milner
No Relationships to Disclose
 
Stephanie Roberson
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Edward Arrowsmith
No Relationships to Disclose